Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keytruda Combination Gives Celyad’s Off-The-Shelf CAR-T A Shot In The Arm

Allogeneics Still Waiting For Breakthrough

Executive Summary

Celyad has been in the CAR-T field for many years, but hopes that a new focus on allogeneic platforms and new targets will put it ahead of competitors. 

You may also be interested in...



Oxford/AstraZeneca Vaccine Shows 70% Efficacy As Company Prepares Approval Filings

Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.

Oxford/AZ Vaccine Hits 70% Efficacy In Phase III Trials

Topline results have produced a lower efficacy rate than seen in the Pfizer and Moderna trials, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.

Pfizer And Moderna’s Cold War On COVID Gets Competitive

Ahead of anticipated emergency use approvals, Pfizer and Moderna are promoting the benefits of their rival mRNA vaccines.

Topics

Related Companies

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel